Triple dosing with high doses of buprenorphine: Withdrawal

Erland Hvittfeldt, MD; Charlotte Gedeon, MD; Ingrid Fridolf, MLS; Anders Håkansson, MD, PhD

doi:10.5055/jom.2015.0281

Authors

Erland Hvittfeldt, MD
Charlotte Gedeon, MD
Ingrid Fridolf, MLS
Anders Håkansson, MD, PhD

DOI:

https://doi.org/10.5055/jom.2015.0281

Keywords:

buprenorphine, norbuprenorphine, opioid maintenance, substance abuse, capillary sampling

Abstract

Background: In maintenance treatment for opiate addiction, buprenorphine can be administered less frequently than daily due to its long half-life.

Objective: To examine the plasma concentration of buprenorphine and norbuprenorphine for 72 hours after a dose of 72 mg and to objectively and subjectively evaluate the correlations between concentrations and withdrawal levels.

Methods: Patients in maintenance treatment with buprenorphine with a daily dose of 24 mg were given a triple dose of 72 mg (n = 9), in an outpatient setting. Blood samples were drawn, and withdrawal symptoms were evaluated objectively and subjectively every 24 hours over 72 hours. Urine and blood toxicology samples were obtained.

Results: The triple dose was generally accepted well with low subjective and objective withdrawal scores. However, two patients aborted the study on day 3 and reported withdrawal symptoms. Benzodiazepine use was confirmed in one while the other likely used unauthorized buprenorphine.

Conclusions: Administration of buprenorphine in three times the daily dose seems acceptable, also in the higher daily maintenance doses (here, 24 mg) used in many clinical settings. Two patients did not tolerate the regimen but, partly due to the outpatient setting, the reasons why are unclear. Further research should be of interest as high buprenorphine doses are becoming more common clinically.

Author Biographies

Erland Hvittfeldt, MD

Malmö Addiction Center, Psychiatry Skane, Malmö, Sweden

Charlotte Gedeon, MD

Department of Clinical Sciences Lund, Division of Psychiatry, Lund University, Lund, Sweden; Methadone Outpatient Facility, Department of Psychiatry Lund, Psychiatry Skane, Lund, Sweden

Ingrid Fridolf, MLS

Methadone Outpatient Facility, Department of Psychiatry Lund, Psychiatry Skane, Lund, Sweden

Anders Håkansson, MD, PhD

Malmö Addiction Center, Psychiatry Skane, Malmö, Sweden; Department of Clinical Sciences Lund, Division of Psychiatry, Lund University, Lund, Sweden

References

Mattick RP, Breen C, Kimber J, et al.: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (review). Cochrane Database Syst Rev. 2014; 2: CD002207.

Kakko J, Svanborg KD, Kreek MJ, et al.: 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet. 2003; 361(9358): 662-668.

Schottenfeld RS, Pakes J, O’Connor P, et al.: Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry. 2000; 47(12): 1072-1079.

Marsch LA, Bickel WK, Badger GJ, et al.: Buprenorphine treatment for opioid dependence: The relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend. 2005; 77(2): 195-204.

Petry NM, Bickel WK, Badger GJ: Examining the limits of the buprenorphine interdosing interval: Daily, every-third-day and every-fifth-day dosing regimens. Addiction. 2001; 96(6): 823-834.

Gross A, Jacobs EA, Petry NM, et al.: Limits to buprenorphine dosing: A comparison between quintuple and sextuple the maintenance dose every 5 days. Drug Alcohol Depend. 2001; 64(1): 111-116.

Kuhlman JJ Jr, Levine B, Johnson RE, et al.: Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction. 1998; 93(4): 549-559.

Chawarski MC, Schottenfeld RS, O’Connor PG, et al.: Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug Alcohol Depend. 1982; 55(1-2): 157-163.

Huang P, Kehner GB, Cowan A, et al.: Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001; 297(2): 688-695.

Jutras-Aswad D, Scimeca MM: Buprenorphine plasma concentration in the management of opioid dependence. Am J Addict. 2011; 20(3): 304-305.

Amass L, Kamien JB, Mikulich SK: Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend. 2001; 61(2): 173-181.

Amass L, Kamien JB, Mikulich SK: Efficacy of daily and alternate-day dosing regimens with the combination buprenorphinenaloxone tablet. Drug Alcohol Depend. 2000; 58(1-2): 143-152.

Pérez de los Cobos J, Martin S, Etcheberrigaray A, et al.: A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug Alcohol Depend. 2000; 59(3): 223-233.

Bickel WK, Amass L, Crean JP, et al.: Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology. 1999; 146(2): 111-118.

Gowing L, Ali R, Dunlop A, et al.: National Guidelines for Medication-Assisted Treatment of Opioid Dependence. Canberra, ACT, Australia: Australian Department of Health, 2014. ISBN: 978-1-74241-944-2. Available at http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/Publishing.nsf/content/AD14DA97D8EE00E8CA257CD1001E0E5D/$File/National_Guidelines_2014.pdf. Accessed May 28, 2015.

Petry NM, Bickel WK, Badger GJ: A comparison of four buprenorphine dosing regimens using open-dosing procedures: Is twice-weekly dosing possible? Addiction. 2000; 95(7): 1069-1077.

Schuh KJ, Johanson CE: Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 1999; 56(1): 55-60.

Chopra MP, Landes RD, Gatchalian KM, et al.: Buprenorphine medication versus voucher contingencies in promoting abstinence from opioids and cocaine. Exp Clin Psychopharmacol. 2009; 17(4): 226-236.

Moore BA, Barry DT, Sullivan LE, et al.: Counseling and directly observed medication for primary care buprenorphine maintenance: A pilot study. J Addiction Med. 2012; 6(3): 205-211.

Center for Substance Abuse Treatment: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.

Centre for Addiction and Mental Health: Buprenorphine/Naloxone for Opioid Dependence. Ontario, Canada: Centre for Addiction and Mental Health, 2011.

Queensland Corrective Services: Administrative form. Guide to the use of Subjective Opiate Withdrawal Scale (SOWS). Queensland Government, 2006. Available at http://www.correctiveservices.qld.gov.au/Resources/Procedures/Support_Services/Documents/spsfrmheroin7daywithdrawal.doc. Accessed May 28, 2015.

Handelsman L, Cochrane KJ, Aronson MJ, et al.: Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987; 13(3): 293-308.

Fareed A, Patil D, Scheinberg K, et al.: Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: A 5-year follow-up. J Addict Dis. 2013; 32(3): 244-251.